(NASDAQ: VOR) Vor Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Vor Biopharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VOR's revenue for 2026 to be $1,561,994,000, with the lowest VOR revenue forecast at $1,561,994,000, and the highest VOR revenue forecast at $1,561,994,000. On average, 1 Wall Street analysts forecast VOR's revenue for 2027 to be $12,159,810,891, with the lowest VOR revenue forecast at $12,159,810,891, and the highest VOR revenue forecast at $12,159,810,891.
In 2028, VOR is forecast to generate $21,799,188,264 in revenue, with the lowest revenue forecast at $21,799,188,264 and the highest revenue forecast at $21,799,188,264.